Five Years Plasma Exchange Experience In Neurological Diseases, Single Center Study

Abstract

Therapeutic plasmapheresis exchange (TPE) treatment is used successfully in many neurological diseases. At our center, TPE is used in many neurological cases in addition to various other diseases. In this study, data of patients who underwent TPE between January 2010 and December 2014 were analyzed. In total, 775 sessions, 114 cycles, and 86 patients’ date were evaluated and analyzed. The median age was 49.8 years. 75 patients were followed in the neurology department and 11 patients were followed in the internal medicine intensive care unit. The most common indications for plasmapheresis were myasthenia gravis, multiple sclerosis, and polyneuropathies (respectively, %35, %21, %9.3). In TPE, hypotension developed much less in those using Fresh Frozen Plasma (FFP) as replacement fluid compared to those using albumin [respectively, 2 (%0.9); 25(%4.4)] (p<0.05). When 114 cycles were evaluated, there was a clinical response in 92% of the cycles. TPE in neurological diseases is considered a safe procedure with a high clinical response rate with minimal side effects.

Keywords

• Complications of plasmapheresis
• Myasthenia gravis
• Neurological diseases
• Plasma Exchange
• Polyneuropathy

Nörolojik Hastalıklarda Beş Yıllık Plazma Değişim Deneyimi, Tek Merkez Çalışması

Abstract

Terapötik plazmaferez değişimi (TPD) tedavisi birçok nörolojik hastalıkta başarıyla kullanılmaktadır. Merkezimizde TPD çeşitli diğer hastalıkların yanı sıra birçok nörolojik vakada kullanılmaktadır. Bu çalışmada, Ocak 2010 ile Aralık 2014 arasında TPD uygulanan hastaların verileri analiz edildi. Toplamda 775 seans, 114 siklus ve 86 hastanın verileri değerlendirildi ve analiz edildi. Ortanca yaş 49,8 idi. 75 hasta nöroloji bölümünde, 11 hasta ise dahiliye yoğun bakım ünitesi'nde takip edildi. Plazmaferez için en sık endikasyonlar myastenia gravis, multipl skleroz ve polinöropatilerdi (sırasıyla %35, %21, %9.3). TPD'de replasman sıvısı olarak Taze Donmuş Plazma (TDP) kullanılanlarda albumin kullanılanlara göre çok daha az hipotansiyon gelişti [sırasıyla 2 (%0.9);25(%4.4)](p<0.05). 114 siklus değerlendirildiğinde siklusların %92’sinde klinik yanıt vardı. Nörolojik hastalıklarda TPD, minimal yan etki ile yüksek klinik yanıt oranına sahip güvenli bir prosedür olarak kabul edilir.

Keywords

• Plazmaferezin komplikasyonları
• Myastenia gravis
• Nörolojik hastalıklar
• Plazma Değişimi

References

1. 1.Ergül M. Eren N. Acil Plazmaferez Gereksinimi; Güngör Ö. Arıcı M. Odabaş AR. Olgularla Nefrolojik Aciller. 1. Baskı. Ankara Nobel Tıp Kitapevi; 2023; 305-312.
2. 2.Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354.
3. 3.Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016 Jun;31(3):149-162.
4. 4.Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013 Jul;28(3):145-284.
5. 5.Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83-177.
6. 6.Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300.
7. 7.Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005 Oct;9(5):391-5.
8. 8.Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec;52(12):2525-32; quiz 2524.

9. 9.McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171-83.
10. 10.Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008 Jan;101(1):63-9.
11. 11.Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;2002(4):CD002275.
12. 12.Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010 Dec;68(6):797-805.
13. 13.Marrodan M, Crema S, Rubstein A, Alessandro L, Fernandez J, Correale J, et al. Therapeutic plasma exchange in MS refractory relapses: Long-term outcome. Mult Scler Relat Disord. 2021 Oct;55:103168.
14. 14.Farooqi MS, Lai Y, Lancaster E, Schmitt SE, Sachais BS. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response. J Clin Apher. 2015 Feb;30(1):8-14.